Curry and colleagues tested an artificial intelligence (AI) software that guided non-radiology specialists in diagnosing ...

In this cohort of women living with HIV (WLWH) in Rwanda, there was an increased risk of delivering a low birth weight (LBW) ...

In this microsimulation model of patients with high cardiovascular risk, an intensive systolic blood pressure (SBP) target of ...

In this systematic review and meta-analysis, estimated blood pressure was found to vary significantly between different ...

Invasive breast cancer recurrence was significantly reduced with extended aromatase inhibitor therapy. 2. No significant ...

Progression-free survival and overall survival were significantly greater in the combination therapy group compared to ...

Higher Post-operative Day 1 (POD1) pain scores were independently associated with increased 30-day infectious and ...

GLP-1 Receptor Agonists and Sight-Threatening Ophthalmic Complications in Patients With Type 2 Diabetes 1. In this cohort of ...

Deal worth up to $1.3 billion brings AI-powered GPCR target discovery into Lilly’s obesity and cardiometabolic pipeline. 2.

GSK paid $500 million upfront for global development rights to Hengrui’s portfolio of up to 12 early-stage assets. 2. Includes a PDE3/4 inhibitor for COPD plus programs in oncology, respiratory, ...

Key Points: 1. Schrödinger discontinued its SGR-2921 CDC7 inhibitor program following two treatment-related deaths in a Phase 1 trial. 2. AML patients showed early signs of benefit, but safety ...

Medical cannabis has a high discontinuation rate among patients with chronic musculoskeletal pain, particularly in the first ...